Related Experiment Videos

A rationale for combination therapy in risk factor management: a mechanistic perspective

R Preston Mason1

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. rpmason@elucidaresearch.com

The American Journal of Medicine
|December 17, 2005
PubMed

Insights

Cardiovascular risk factors impair endothelial function, reducing nitric oxide (NO) release. Amlodipine and atorvastatin show synergistic effects in stimulating NO, potentially improving endothelial health.

Area of Science:

  • Cardiovascular medicine
  • Endothelial biology
  • Pharmacology

Background:

  • Endothelial dysfunction is a key factor in atherogenesis and coronary heart disease.
  • Cardiovascular risk factors like hypertension and hyperlipidemia impair endothelial function, reducing nitric oxide (NO) bioavailability.
  • Oxidative stress mechanisms are implicated in the synergistic negative effects of multiple risk factors on endothelial health.

Purpose of the Study:

  • To explore the impact of cardiovascular risk factors on endothelial function.
  • To investigate the direct effects of amlodipine and atorvastatin on endothelial nitric oxide (NO) bioavailability.
  • To discuss the clinical implications of these agents' synergistic effects on NO release for cardiovascular risk management.

Main Methods:

  • Review of existing literature on endothelial dysfunction and cardiovascular risk factors.
  • Analysis of experimental evidence at the cellular level regarding amlodipine and atorvastatin.
  • Discussion of clinical implications in the context of risk factor management.

Main Results:

  • Cardiovascular risk factors contribute to endothelial dysfunction by reducing nitric oxide (NO) release and impairing vasodilation.
  • Hypertension and hyperlipidemia exhibit synergistic detrimental effects on endothelial function, likely via oxidative stress.
  • Amlodipine and atorvastatin were shown to stimulate NO release from human endothelial cells in a highly synergistic manner.

Conclusions:

  • Endothelial dysfunction is a critical link between cardiovascular risk factors and disease.
  • Amlodipine and atorvastatin possess properties that directly enhance NO bioavailability.
  • The synergistic stimulation of NO release by these agents offers potential therapeutic benefits in managing cardiovascular risk.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...